In humans, neurodegenerative diseases such as Alzheimer’s disease lead to a depletion of NRGN expression in the brain and an elevation of NRGN levels in the cerebrospinal fluid, changes that are associated with diminished cognitive performance [45,46,47]. Here, NRGN is linked to early-onset autosomal dominant Alzheimer disease.